Background

The ongoing threat posed by coronaviruses, including SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) that caused the recent COVID-19 pandemic, as well as past outbreaks such as SARS-CoV and MERS-CoV, have underscored the critical need for effective therapeutics. The evolving nature of these viruses, along with concerns about future outbreaks at regular intervals and the imperative to safeguard vulnerable populations globally have driven ongoing research and investment for the therapeutics market.

The COVID-19 pandemic caused by SARS-CoV-2 has led to a global health crisis, with evolving variants reducing the efficacy of existing vaccines. Recognizing the threat posed by various coronaviruses, there is an urgent need to develop antiviral drugs against a variety of coronaviruses. Central to this effort is